DERM Quote, Financials, Valuation and Earnings

Eton Pharmaceuticals has a net margin of -16.34% compared to Journey Medical's net margin of 6.07%. Journey Medical's return on equity of -125.77% beat Eton Pharmaceuticals's return on equity of -35.45%.

Journey Medical has a consensus price target of --, signalling upside risk potential of 122.72%. On the other hand Eton Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 18.48%. Given that Journey Medical has higher upside potential than Eton Pharmaceuticals, analysts believe Journey Medical is more attractive than Eton Pharmaceuticals.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eton Pharmaceuticals has a beta of 1.394, suggesting its more volatile than the S&P 500 by 39.406%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eton Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Eton Pharmaceuticals pays out -- of its earnings as a dividend.

Journey Medical quarterly revenues are $14.6M, which are larger than Eton Pharmaceuticals quarterly revenues of $10.3M. Journey Medical's net income of -$2.4M is lower than Eton Pharmaceuticals's net income of $627K. Notably, Journey Medical's price-to-earnings ratio is -- while Eton Pharmaceuticals's PE ratio is 79.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 1.55x versus 9.48x for Eton Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of -16.34% compared to Journey Medical's net margin of -87.96%. Journey Medical's return on equity of -125.77% beat Fortress Biotech's return on equity of --.

Journey Medical has a consensus price target of --, signalling upside risk potential of 122.72%. On the other hand Fortress Biotech has an analysts' consensus of -- which suggests that it could grow by 691.9%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.703, suggesting its more volatile than the S&P 500 by 70.299%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Fortress Biotech pays out -14.46% of its earnings as a dividend.

Journey Medical quarterly revenues are $14.6M, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Journey Medical's net income of -$2.4M is higher than Fortress Biotech's net income of -$12.9M. Notably, Journey Medical's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 1.55x versus 0.35x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Heron Therapeutics has a net margin of -16.34% compared to Journey Medical's net margin of -14.78%. Journey Medical's return on equity of -125.77% beat Heron Therapeutics's return on equity of --.

Journey Medical has a consensus price target of --, signalling upside risk potential of 122.72%. On the other hand Heron Therapeutics has an analysts' consensus of -- which suggests that it could grow by 279.75%. Given that Heron Therapeutics has higher upside potential than Journey Medical, analysts believe Heron Therapeutics is more attractive than Journey Medical.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Heron Therapeutics has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.471%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Heron Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Heron Therapeutics pays out -- of its earnings as a dividend.

Journey Medical quarterly revenues are $14.6M, which are smaller than Heron Therapeutics quarterly revenues of $32.8M. Journey Medical's net income of -$2.4M is higher than Heron Therapeutics's net income of -$4.8M. Notably, Journey Medical's price-to-earnings ratio is -- while Heron Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 1.55x versus 1.74x for Heron Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -16.34% compared to Journey Medical's net margin of -49.65%. Journey Medical's return on equity of -125.77% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Journey Medical has a consensus price target of --, signalling upside risk potential of 122.72%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Journey Medical, analysts believe NovaBay Pharmaceuticals is more attractive than Journey Medical.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Journey Medical quarterly revenues are $14.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Journey Medical's net income of -$2.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Journey Medical's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 1.55x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.